Quarterly report pursuant to Section 13 or 15(d)

5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2)

v3.10.0.1
5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Total stock-based compensation expense $ 577,581 $ 505,730 $ 1,627,756 $ 1,052,970
Research and development        
Total stock-based compensation expense 84,588 141,405 246,231 262,822
Plasma centers        
Total stock-based compensation expense 7,836 10,341 22,682 36,288
Selling, general and administrative        
Total stock-based compensation expense 444,651 331,946 1,245,702 726,062
Cost of goods sold        
Total stock-based compensation expense $ 40,506 $ 22,038 $ 113,141 $ 27,798